IRON · Disc Medicine, Inc.

Summary

Disc Medicine, Inc. approved a restructuring plan on February 26, 2026, reducing its workforce by approximately 20% primarily in commercial and supporting functions, following an FDA complete response letter on February 13, 2026, for its bitopertin NDA. The Company expects $2.0 million in aggregate charges, mainly severance, in Q1 2026.

Key takeaways

• Board approved Restructuring Plan on February 26, 2026
• Workforce reduction of approximately 20%
• Reductions primarily in commercial functions and certain supporting functions
• Triggered by FDA complete response letter on February 13, 2026, for bitopertin NDA treating erythropoietic protoporphyria and X-linked protoporphyria
• Expected aggregate charges of $2.0 million, primarily severance
• Implementation to complete in Q2 2026; charges primarily in Q1 2026